Research output per year
Research output per year
Search results
-
2023
Accepted poster session at ImmunoRad 2023: Targeted alpha therapy using Actinium-225 radiolabeled single domain antibodies induces antigen-specific immune responses and instills immunomodulation both systemically and at the tumor microenvironment
Ertveldt, T., Krasniqi, A., Ceuppens, H., Puttemans, J., Dekempeneer, Y., De Jonghe, K., de Mey, W., Lecocq, Q., De Vlaeminck, Y., Awad, R. M., Goyvaerts, C., De Veirman, K., Morgenstern, A., Bruchertseifer, F., Keyaerts, M., Devoogdt, N., D'Huyvetter, M. & Breckpot, K., 27 Sep 2023.Research output: Unpublished contribution to conference › Poster
-
2020
Investigating immune activation upon beta targeted radionuclide therapy using anti-CD20 single domain antibody fragments in melanoma
Ertveldt, T., Dekempeneer, Y., De Beck, L., Goyvaerts, C., Lecocq, Q., De Vlaeminck, Y., Awad, R. M., Devoogdt, N., Keyaerts, M., D'Huyvetter, M., Breckpot, K. & Krasniqi, A., 7 Feb 2020, p. page 79. 1 p.Research output: Unpublished contribution to conference › Poster
Open AccessFile23 Downloads (Pure) -
Nanobody-mediated imaging of PD-L1 provides a rationale to combine Galsome vaccination with immune checkpoint blockade
Ertveldt, T., Meulewaeter, S., Lentacker, I., Verbeke, R., De Smedt, S., Olarte, O., Barbé, K., Keyaerts, M., Dewitte, H. & Breckpot, K., 7 Feb 2020, p. 1. 1 p.Research output: Unpublished contribution to conference › Poster
Open AccessFile16 Downloads (Pure) -
2019
Targeted radionuclide therapy using anti-CD20 sdAbs: assessment of immune-activation post treatment with beta-emitting radionuclides
Ertveldt, T., Krasniqi, A., Keyaerts, M., Goyvaerts, C., Lecocq, Q., De Vlaeminck, Y., Awad, R. M., De Beck, L., Dekempeneer, Y., Devoogdt, N., D'Huyvetter, M. & Breckpot, K., 18 Oct 2019.Research output: Unpublished contribution to conference › Poster